Literature DB >> 24956549

Evidence of mononuclear cell preactivation in the fasting state in polycystic ovary syndrome.

Frank González1, John P Kirwan2, Neal S Rote3, Judi Minium3.   

Abstract

OBJECTIVE: We evaluated mononuclear cell (MNC) preactivation in women with polycystic ovary syndrome (PCOS) by examining the effect of in vitro lipopolysaccharide (LPS) exposure on cytokine release in the fasting state. STUDY
DESIGN: Twenty women with PCOS (10 lean, 10 obese) and 20 weight-matched controls (10 lean, 10 obese) volunteered for study participation. Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) release was measured from mononuclear cells isolated from fasting blood samples and cultured in the presence and absence of LPS. Plasma IL-6 was measured from the same fasting blood samples. Insulin sensitivity was derived from an oral glucose tolerance test using the Matsuda index, and truncal fat was measured by dual-energy x-ray absorptiometry.
RESULTS: The percent change from baseline in TNF-α and IL-6 release from MNC following LPS exposure was increased (P < .04) in lean and obese women with PCOS and obese controls compared with lean controls. Plasma IL-6 was increased (P < .02) in obese women with PCOS compared with lean women with PCOS, which in turn was increased (P < .02) compared with lean controls. The MNC-derived TNF-α and IL-6 responses from MNCs were negatively correlated with insulin sensitivity (P < .03) and positively correlated with testosterone (P < .03) and androstenedione (P < .006) for the combined groups. Plasma IL-6 was positively correlated with percentage truncal fat (P < .008).
CONCLUSION: In PCOS, increased cytokine release from MNCs following LPS exposure in the fasting state reveals the presence of MNC preactivation. Importantly, this phenomenon is independent of obesity and may contribute to the development of insulin resistance and hyperandrogenism in PCOS. In contrast, the source of plasma IL-6 elevations in PCOS may be excess adiposity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  inflammation; lipopolysaccharide; mononuclear cell preactivation

Mesh:

Substances:

Year:  2014        PMID: 24956549      PMCID: PMC4253610          DOI: 10.1016/j.ajog.2014.06.044

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  38 in total

1.  Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans.

Authors:  Saverio Cinti; Grant Mitchell; Giorgio Barbatelli; Incoronata Murano; Enzo Ceresi; Emanuela Faloia; Shupei Wang; Melanie Fortier; Andrew S Greenberg; Martin S Obin
Journal:  J Lipid Res       Date:  2005-09-08       Impact factor: 5.922

2.  Tumor necrosis factor-alpha stimulates proliferation of rat ovarian theca-interstitial cells.

Authors:  R Z Spaczynski; A Arici; A J Duleba
Journal:  Biol Reprod       Date:  1999-10       Impact factor: 4.285

3.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

4.  Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome.

Authors:  Frank González; Chang Ling Sia; Frank Z Stanczyk; Hilary E Blair; Michelle E Krupa
Journal:  Endocrine       Date:  2012-07-01       Impact factor: 3.633

5.  Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease.

Authors:  Veysel Fenkci; Semin Fenkci; Mehmet Yilmazer; Mustafa Serteser
Journal:  Fertil Steril       Date:  2003-07       Impact factor: 7.329

6.  Glucose ingestion stimulates atherothrombotic inflammation in polycystic ovary syndrome.

Authors:  Frank González; John P Kirwan; Neal S Rote; Judi Minium
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-12-18       Impact factor: 4.310

7.  Insulin resistance: an atherothrombotic syndrome. The Leeds family study.

Authors:  Mark S Freeman; Michael W Mansfield; Jenny H Barrett; Peter J Grant
Journal:  Thromb Haemost       Date:  2003-01       Impact factor: 5.249

8.  Circulating mononuclear cells in the obese are in a proinflammatory state.

Authors:  Husam Ghanim; Ahmad Aljada; Deborah Hofmeyer; Tufail Syed; Priya Mohanty; Paresh Dandona
Journal:  Circulation       Date:  2004-09-13       Impact factor: 29.690

9.  In vitro evidence that hyperglycemia stimulates tumor necrosis factor-alpha release in obese women with polycystic ovary syndrome.

Authors:  F González; N S Rote; J Minium; J P Kirwan
Journal:  J Endocrinol       Date:  2006-03       Impact factor: 4.286

10.  Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.

Authors:  Bart C J M Fauser; Basil C Tarlatzis; Robert W Rebar; Richard S Legro; Adam H Balen; Roger Lobo; Enrico Carmina; Jeffrey Chang; Bulent O Yildiz; Joop S E Laven; Jacky Boivin; Felice Petraglia; C N Wijeyeratne; Robert J Norman; Andrea Dunaif; Stephen Franks; Robert A Wild; Daniel Dumesic; Kurt Barnhart
Journal:  Fertil Steril       Date:  2011-12-06       Impact factor: 7.329

View more
  3 in total

1.  A lower-carbohydrate, higher-fat diet reduces abdominal and intermuscular fat and increases insulin sensitivity in adults at risk of type 2 diabetes.

Authors:  Barbara A Gower; Amy M Goss
Journal:  J Nutr       Date:  2014-12-03       Impact factor: 4.798

2.  High Serum Tumor Necrosis Factor-Alpha Levels in Women with Polycystic Ovary Syndrome: A Meta-Analysis.

Authors:  Lingling Gao; Yang Gu; Xianghua Yin
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

3.  A Rat Model of Maternal Polycystic Ovary Syndrome Shows that Exposure to Androgens In Utero Results in Dysbiosis of the Intestinal Microbiota and Metabolic Disorders of the Newborn Rat.

Authors:  Tuohetimulati Gulan; Tusufuhan Yeernuer; Shuang Sui; Niziya Mayinuer
Journal:  Med Sci Monit       Date:  2019-12-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.